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Abstract
Canine coagulation factor VII (FVII) deficiency can be hereditary or acquired and may cause life
threatening bleeding episodes if untreated. FVII procoagulant activity can be measured by FVII
activity (FVII:C), but assays for measurement of canine specific FVII antigen (FVII:Ag) have not
been available to date. In this study, a canine specific ELISA for measurement of FVII:Ag in
plasma was developed and validated. The FVII:Ag ELISA correctly diagnosed homozygous and
heterozygous hereditary FVII deficiency. Together with activity based assays, such as FVII:C, the
FVII:Ag ELISA should be valuable in the diagnosis of hereditary canine FVII deficiency.
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Introduction
Canine coagulation factor VII (FVII) deficiency is a bleeding disorder with, primarily, a
relatively mild phenotype (Mustard et al., 1962). Nevertheless, if untreated, it can result in
life threatening bleeding and affected animals require intensive care (Spurling et al., 1974;
Wheeler et al., 1984). This is also true in humans, where more than 100 unique genetic
variants of hereditary FVII deficiency have been identified (Mariani et al., 2005). Clinical
cases in humans range from asymptomatic to patients with severe haemorrhagic tendencies
(Mariani et al., 1998) and significant mortality in neonates (Ragni et al., 1981).
Congenital FVII deficiency is well known in Beagles (Spurling et al., 1972), where the
deficiency is caused by a G96E substitution in FVII (cFVII); as many as one third of
Beagles may carry the defective gene (Wilhelm et al., 2001; Callan et al., 2006). Hereditary
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FVII deficiency (G96E variant) is also seen in other breeds, such as the Alaskan Klee Kai
(Kaae et al., 2007). FVII deficiency may also be acquired, either due to decreased
production of functional FVII (e.g. rodenticide poisoning and hepatic diseases), due to
consumption (e.g. disseminated intravascular coagulation, DIC) or due to dilution
coagulopathies secondary to fluid resuscitation. One case of combined congenital and
acquired FVII deficiency has been reported as a result of rodenticide poisoning in a Beagle
(Daly and Giger, 2007).
Quantification of canine FVII clotting activity in prothrombin time (PT)-based assays has
proven feasible but difficult (Mischke et al., 2003). To detect canine FVII deficiency by
means of the standard PT assay, the functional factor level must be <39% (Mischke et al.,
2003), i.e. decreased by at least 18% below the normal reference (Mischke, 2001). Due to a
lack of appropriate assays, precise canine FVII:Ag levels have not been determined (Callan
et al., 2006). This lack of sufficiently sensitive assays is relevant both to canine medicine
and experimental models used in preclinical research (Callan et al., 2006). Therefore, an
accurate assay to detect FVII antigen (FVII:Ag) in dogs is required.
The aims of the current study were to develop and validate a canine specific ELISA to
accurately measure FVII:Ag in canine plasma, to apply the FVII:Ag assay in the diagnostic
work up of canine hereditary FVII deficiency and to determine whether the FVII:Ag assay is
superior to existing PT and FVII activity (FVII:C) assays in accurately identifying carriers
of hereditary FVII deficiency.
Materials and methods
Animals
Plasma samples from 87 dogs were included in the study. Of these 87 dogs, 71 were client
owned dogs submitted to the Onderstepoort Veterinary Academic Hospital, Faculty of
Veterinary Science, University of Pretoria, and 16 were colony dogs from two different
colonies: four FVII deficient homozygotes from the Chapel Hill colony at the University of
North Carolina and 12 obtained from a commercial supplier for other purposes (3 FVII
deficient heterozygotes and 9 unaffected). The colony dogs were housed in the Chapel Hill
colony (FVII deficient homozygotes) or in an enriched environment at Novo Nordisk,
Denmark (heterozygotes and unaffected dogs). Colony dogs were genotyped according to
Callan et al. (2006).
A plasma pool from eight clinically healthy client owned dogs (3 mixed breed, 2 Border
Terriers, 1 Labrador mix, 1 Whippet, 1 Shetland Sheepdog) was used as FVII:Ag reference
material and for calibration of the FVII:C assay. The plasma pool was produced at the
Department of Small Animal Clinical Sciences, Faculty of Life Sciences, University of
Copenhagen. The dogs were characterised ‘free from overt disease’ based on clinical
examination, complete blood count (CBC), biochemistry and a coagulation profile
consisting of prothrombin time (PT), activated partial thromboplastin time (aPTT), D-
Dimer, fibrinogen and platelet count.
Four mice (RBF/DnJ, Jackson Laboratory), housed at Novo Nordisk, Denmark, were used
for antibody production. Experiments were approved by the Animal Use and Care
Committee at the University of Pretoria (approval number V010/07), the Institutional
Animal Care and Use Committee at the University of North Carolina (approval number
08-134.0-B), the Danish Animal Experiments Council and the Danish Ministry of Justice
(approval numbers: dogs: 2007/561-1276; mice: 2007/561-1413) and by the Animal Use and
Ethics committee of the Department of Small Animal Clinical Sciences, Faculty of Life
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Sciences, University of Copenhagen. Written consent was obtained before sampling of client
owned dogs.
Sample collection
Whole blood was collected into citrated plastic tubes (Vacutainer, Greiner Bio-One) by
careful venipuncture using minimum stasis and a 21 G butterfly needle. Plasma was isolated
by centrifugation, separated into aliquots, frozen immediately after sampling and stored at
−80 °C until it was shipped on dry ice to the site of analysis. After arrival in Denmark,
plasma samples were stored at −80 °C until the time of the assay.
Canine specific monoclonal anti-FVII antibodies
Canine specific monoclonal antibodies (mAbs) were raised in mice by immunisation with
recombinant canine FVIIa (rcFVIIa) (Knudsen et al., 2010) using standard procedures
(Appendix A supplementary material).
ELISA development
Microtitre plates (96-wells/plate) were coated with the capture antibody (‘F11’) at 0.5 μg/
mL (antibody concentration initially optimised in a matrix setup) in 100 μL coating buffer
(10 mM NaHCO3, pH 9.6) overnight at 4 °C. Blocking was completed by incubation for 15
min at room temperature (RT) with 300 μL washing buffer containing 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES), 150 mM NaCl and 0.02% Tween
80 (pH 7.4), before washing the plates three times with 300 μL washing buffer using an
automated plate washer (ELx50, BioTek Instruments).
Samples were pre-diluted 1:100 with dilution buffer consisting of washing buffer with 0.1%
W/V bovine serum albumin (BSA) substituted for Tween 80. Pre-dilution was optimised in
initial experiments; although 1:100 was selected as the optimal pre-dilution, alternative pre-
dilutions, e.g. 1:25 of FVII deficient plasma, also performed well in the assay. Two hundred
microlitres of pre-diluted samples were incubated for 60 min at RT in each test well of the
microtitre plate. After washing the plate three times using 300 μL washing buffer each time,
200 μL of 1.0 μg/mL horse radish peroxidase (HRP)-conjugated detector antibody (‘F20-
HRP’; HRP conjugated using Lightning-Link HRP, Innova Biosciences) was added to the
wells and incubated for 30 min at RT; the concentration of the detector antibody was
optimised using a matrix setup. The plate was washed three times again, then 100 μL of a
commercial 3,3′,5,5′-tetramethylbenzidine (TMB) solution (T4444, Sigma–Aldrich) was
added to wells and incubated for 20 min at RT. The enzymatic reaction was quenched by
addition of 100 μL 1 M sulphuric acid.
Colour development was quantified using a microplate spectrophotometer (SpectraMax 340,
Molecular Devices), detecting the optical density at 450 nm (OD450nm). Sample FVII:Ag
was calculated using SOFTmax Pro (Molecular Devices) by comparing OD450nm signals
from a seven point second order standard curve created with 0.3–30 nmol/L recombinant
canine FVII. The stock concentration of the reference standard was determined using a
micro-volume spectrophotometer (Knudsen et al., 2010).
Analytical performance
Inaccuracy—Inaccuracy was assessed in spike-recovery and dilution linearity
experiments. In spike-recovery experiments, zymogen recombinant canine FVII (rcFVII)
was spiked into pooled FVII deficient plasma from the four G96E homozygotes included in
this study, in human normal plasma (HemosIL Calibration plasma, Instrumentation
Laboratory), human FVII deficient plasma (Helena Laboratories), in dilution buffer and in
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Tris-buffered saline (TBS)/BSA (50 mM Tris, 100 mM NaCl, 1% V/V BSA, pH 7.4) to
create samples with low (3 nM), medium (15 nM) and high (27 nM) concentrations of
FVII:Ag.
The samples were then assayed in duplicate in three separate runs and the baseline corrected
recovery was reported as a percentage relative to the theoretical FVII:Ag content of the
sample. Dilution linearity was assessed in three separate runs with duplicate measurements
of pooled normal canine plasma serially diluted to yield samples with 100% (undiluted),
75%, 50%, 25%, 10%, 5% and 1% FVII:Ag.
Detection limit and analytical imprecision—The detection limit was defined as the
mean signal plus three standard deviations (SD) obtained from a buffer blank assayed in 10
replicates. To survey analytical imprecision in terms of the intra- and inter-assay coefficient
of variation (CV), three specimens with low, medium and high (i.e. normal) concentrations
of FVII:Ag, prepared by mixing plasma from unaffected wild type (wt/wt) and FVII
deficient (G96E/G96E) dogs, were analysed in 10 replicates for intra-assay characterisation
and in duplicates in five individual experiments for inter-assay characterisation.
Freeze–thaw and stability at −20 °C—Freeze–thaw stability was examined by
submitting samples with different plasma FVII:Ag content to repeated freezing on dry ice
for approximately 3 min then thawing in a water bath at room temperature, before assaying
all samples in duplicates in the same run. Aliquots were prepared from the same starting
material and then one sample was taken aside (before freeze–thawing) and kept at 4 °C. The
remaining samples were then submitted to the first freeze–thaw cycle. Then, one additional
sample was taken aside and kept at 4 °C, together with the non-frozen sample. The
procedure was repeated until all samples had undergone 0–5 freeze–thaw cycles. Total pre-
analytical processing time was approximately 30 min. The experiment also included an
identical setup with rcFVII at 30, 15 and 7.5 nmol/L in TBS/BSA buffer. Stability at −20 °C
was evaluated by repeated duplicate measurements, 125 days apart, of pooled normal canine
plasma kept at −20 °C.
Measurements in the presence of human FVIIa—The ability of the assay to
correctly measure canine FVII:Ag in the presence of recombinant human FVIIa (rhFVIIa)
was assessed in experiments (n = 3) with spiking of normal canine plasma with rhFVIIa at
25, 50, 100 and 250 nmol/L (duplicate measurements for each concentration in each
experiment).
Conventional coagulation profile and FVII:C assay—All haemostasis tests were
performed at the Central Laboratory, Department of Small Animal Clinical Sciences,
Faculty of Life Sciences, University of Copenhagen, employing commercial reagents in a
validated setup with an automated coagulometer (ACLTop 500, Instrumentation Laboratory)
(Wiinberg et al., 2009): aPTT (SynthAFax, Instrumentation Laboratory), PT
(RecombiPlasTin 2G, Instrumentation Laboratory), D-dimer (D-Dimer Single Tests,
NycoCard READER II, Medinor A/S), fibrinogen (RecombiPlasTin 2G, Instrumentation
Laboratory) and FVII activity (FVII:C). FVII:C measurements were completed (in a PT
based assay) with a commercially available human test system comprising human tissue
factor (Recombi-PlasTin 2G, Instrumentation Laboratory) and human FVII depleted
substrate plasma (Factor VII deficient plasma, Instrumentation Laboratory) and calibrated
with a canine plasma pool.
Method comparison: FVII:C vs. FVII:Ag in samples from dogs with varying
FVII levels—As part of the evaluation of analytical performance, the ability of the FVII:Ag
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assay to measure canine FVII was assessed indirectly by performing a method comparison
of parallel FVII:C and FVII:Ag measurements where high correlation was expected, as
previously demonstrated with human samples (Patrassi et al., 1993; Takamiya and
Yoshioka, 1996; Hunault et al., 1997). Seventy-one samples from dogs with clinical
babesiosis available from another study were measured in both assays to challenge the
FVII:Ag assay with samples expected to vary widely in FVII content. To allow direct
comparison of FVII:C (activity) and FVII:Ag (antigen), results were given relative to a
normal pool (%). Method comparison was performed according to Jensen and Kjelgaard-
Hansen (2006).
Comparison of the diagnostic performance of prothrombin time, FVII:C and
FVII:Ag assays in detection of hereditary FVII deficiency—To assess which assay
potentially would be best suited to diagnose hereditary FVII deficiency (G96E variant),
plasma from the 16 colony dogs (4 G96E/G96E homozygotes, 3 G96E/wt heterozygotes, 9
wt/wt homozygotes) were assayed for PT, FVII:C and FVII:Ag.
Acceptance criteria and statistical analyses—Analytical imprecision was assessed
by standard methods (Jensen and Kjelgaard-Hansen, 2010). The intra-assay and inter-assay
inaccuracies measured as CV were deemed to be acceptable when <10% and <20%,
respectively.
A detection limit of 5% FVII:Ag (compared to a normal pool) was defined as acceptable,
since affected Beagles with hereditary FVII deficiency have been reported to have plasma
FVII:C ≤ 5% normal (Callan et al., 2006; Withnall and Giger, 2006). Thus, FVII:Ag ≤ 5%
would imply an unequivocal diagnosis of FVII deficiency.
Accuracy was deemed to be acceptable if recovery was 90–110% in spike-recovery
experiments and if data from dilution linearity experiments could be fitted by linear
regression with a correlation coefficient (r2) above > 0.99 to a straight line not significantly
different from a line representing agreement (FVII:Ag[theoretical] = FVII:Ag[measured]).
Freeze thaw stability and storage stability at −20 °C were judged to be acceptable if mean
recorded FVII:Ag values of thawed and stored samples were within 90–110% of mean
FVII:Ag from the unfrozen original sample, respectively.
Agreement between FVII:C and FVII:Ag measurements was assessed by Passing– Bablock
linear regression and was deemed to be acceptable when the slope and intercept were not
statistically different from 1 and 0, respectively. Cusum test was used to identify potential
deviation from linearity. The nature of possible disagreement was assessed by Bland–
Altman plotting with criteria for combined inherent imprecision (Jensen and Kjelgaard-
Hansen, 2006).
To evaluate the discriminatory power of PT, FVII:C and FVII:Ag assays in distinguishing
between wt homozygotes (wt/wt), FVII deficient heterozygotes (G96E/wt) and FVII
deficient homozygotes (G96E/G96E), the measured levels of PT, FVII:C and FVII:Ag in the
three groups were compared by means of the Mann–Whitney U-test and receiver operator
characteristic (ROC) curve analysis (Gardner and Greiner, 2006). The acceptance limit for
diagnostic capacity was set at AUCROC > 0.5 and classified as good with an AUCROC≥0.9.
Tests with AUCROC≥0.5 were compared to detect possible superiority of one test vs.
another, i.e. test A is superior to test B if AUCROC(test A) > AUCROC(test B).
All data were reported as ‘mean’ or ‘mean with 95% confidence interval (CI95)′ unless
otherwise noted. Where single experiments were reported, ‘means’ represents the mean of
Knudsen et al. Page 5













duplicate measurements. Similarly, when experiments were repeated, reported ‘means’
represent means of mean duplicate values from all experiments. Statistical significance was
set at P < 0.05. Calculations were performed in GraphPad Prism 5.02, Medcalc 6.0 or
Microsoft Office Excel 2003 SP3.
Results
Analytical performance
A minimally activated rcFVII preparation (Knudsen et al., 2010) was used for standard
curves (Fig. 1); control experiments replacing zymogen rcFVII with activated rcFVIIa did
not identify different binding of rcFVII and rcFVIIa by the two mAbs used in the ELISA
(data not shown). Thus, the ELISA measured canine FVII:Ag as total FVII:Ag + FVIIa:Ag.
The detection limit, using a 1:100 sample pre-dilution, was 1.2% FVII:Ag compared to
normal pooled plasma (FVII:Ag(Blanks): 0.918 ± 0.093%; mean ± SD). The assay could be
modified with better resolution at lower FVII:Ag concentrations by applying less dilute
sample formulations, e.g. by using a 1:25 pre-dilution instead of the 1:100 used in the
present study, without adverse effects on precision and reproducibility (data not shown).
Analytical imprecision within and between assays was acceptable for all samples (Table 1).
Accuracy criteria were held for samples with low, medium and high FVII:Ag in spike-
recovery experiments; mean recovery was 97–106% in canine FVII deficient plasma, 91–
105% in human plasma and 96–102% in buffer (Table 2).
Dilution linearity met criteria; CI95 for slope and intercept were [0.956; 1.024] and [−0.275;
0.518], respectively (Fig. 2). Freeze–thaw stability was acceptable for all samples submitted
to ≤2 freeze–thaw cycles. Specimens with low FVII:Ag did not hold stability criteria with
three or more freeze–thaw cycles. Specimens with medium and high FVII:Ag held criteria
through all five freeze–thaw cycles (Table 3). Freezer stability at −20 °C was acceptable
throughout the 4 month study period. Measurements of FVII:Ag in normal plasma spiked
with 25–250 nmol/L rhFVIIa ranged from 98 to 103% of unspiked controls, demonstrating
no cross reactivity of the applied antibodies to rhFVIIa.
Method comparison: FVII:C vs. FVII:Ag in samples from dogs with varying FVII levels
Activity and antigen based measurements of FVII, i.e. FVII:C and FVII:Ag, respectively, in
71 clinical samples from dogs with clinical babesiosis (hence at risk of having acquired FVII
deficiency), spanned a range from 6.7% FVII:C and 9.1% FVII:Ag to ≥150% FVII:C (upper
limit of working range) and FVII:Ag when compared to a normal pooled plasma with a FVII
concentration of 19.4 nmol/L FVII:Ag. Measurements were significantly correlated between
the two methods; Passing–Bablock regression yielded CI95 [0.97; 1.34] for slope and
[−17.81; 5.84] for intercept (Fig. 3A). No systematic error was identified; linear regression
of residuals yielded CI95 [−0.16; 0.16] for slope and [−12.73; 12.73] for intercept. Although
no systematic error was identified, a total of 43 residuals (61%) were outside, 19 (27%)
above and 24 (34%) below the bounds of the expected interval defined by the combined
inherent imprecision of the FVII:C and FVII:Ag assays (Fig. 3B), demonstrating random
disagreement in excess of combined imprecision.
Comparison of the diagnostic performance of PT, FVII:C and FVII:Ag assays for detection
of hereditary FVII deficiency
With FVII:C and FVII:Ag, but not PT, significantly different mean FVII levels were
identified between wt/wt homozygotes and wt/G96E heterozygotes, i.e. between groups of
wild type and carrier dogs. At the individual dog level, FVII:C values overlapped between
wild type and carrier animals, while this was not observed for FVII:Ag. In comparison,
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different mean PT, FVII:C and FVII:Ag values were identified between wt/wt (healthy wild
type) and G96E/G96E (affected FVII deficient) homozygotes (Table 4 and Fig. 4A–C).
Using ROC analysis, both FVII:C and FVII:Ag assays had significant diagnostic abilities in
distinguishing between healthy wild type homozygotes (wt/wt) and heterozygote carriers of
the FVII deficiency gene (wt/G96E), with both FVII:C and FVII:Ag demonstrating high
diagnostic performance: AUCROC(FVII:C) = 0.936 and AUCROC(FVII:Ag) = 1.0 (Fig. 4E and
F). No significant difference was demonstrated between diagnostic performances of FVII:C
and FVII:Ag (ΔAUCROC = [−0.070; 0.144], P = 0.5), i.e. the null hypothesis H0:
AUCROC(FVII:C) = AUCROC(FVII:Ag) was not rejected.
In contrast to FVII:C and FVII:Ag, PT was of no appreciable value in distinguishing
between dogs as either healthy wild type or carriers: AUCROC = 0.741 (CI95: [0.453; 1.0]; P
= 0.230) (Fig. 4D). When used to distinguish between healthy wild type (wt/wt) and FVII
deficient homozygotes (G96E/G96E), all three assays demonstrated diagnostic abilities as
demonstrated by an AUCROC of 1.0 (P < 0.01) for PT, FVII:C and FVII:Ag, respectively.
Discussion
Timely diagnosis of hereditary FVII deficiency is important for optimal treatment of
individual animals and tools are needed to guide rational breeding, with the aim of limiting
or eliminating hereditary FVII deficiency in dog populations (Callan et al., 2006). To date,
diagnosis of hereditary FVII deficiency has been based on gene analysis detecting a single
causative mutation in exon 5 of the FVII gene (F7), because measurements of plasma FVII
coagulant activity have not been able to unambiguously detect carrier dogs and a canine
FVII ELISA has not been available (Callan et al., 2006). The validated FVII:Ag assay
reported here offers an alternative and precise method to quantify canine FVII in dog
plasma.
The ELISA developed in this study used a matched pair of murine mAbs to canine FVII and
measured canine FVII:Ag as total FVII + FVIIa antigen. Imprecision, in terms of intra- and
inter-assay variation was acceptable for plasma samples with low, medium and high
FVII:Ag. To enhance clinical applicability, a reference population must be sampled before a
normal FVII:Ag reference range can be established (Geffre et al., 2009). However, from the
present study, it seems that normal canine FVII:Ag may be approximately 20 nmol/L, which
is twice the concentration in humans (Fair, 1983). The antibodies used were counter-
screened against rhFVIIa and experiments showed that FVII:Ag measurements were
unaffected by 250 nmol/L rhFVIIa. Thus, the assay will correctly measure canine FVII, even
in dogs that have been treated with rhFVIIa (Withnall and Giger, 2006).
Additionally, no matrix effect was observed in spike-recovery experiments and hence the
assay should reliably measure FVII:Ag in a wide range of sample materials. Good freeze–
thaw and stability at −20 °C was observed; accordingly, in a clinical study, it should be
feasible to collect samples over a 4 month period and to analyse them in batches after
completing the sample collection phase.
To demonstrate the ability to measure FVII:Ag over a wide range of concentrations, the
study included a comparison of the FVII:C and FVII:Ag assays as part of the validation
procedure. In both assays, plasma FVII was measured in samples from dogs with clinical
babesiosis expected to have varying levels of plasma FVII due to consumption and
haemoconcentration. As expected from human studies, FVII:C and FVII:Ag were correlated
and there was no systematic error. However, the random difference between plasma FVII as
assessed by FVII:C and FVII:Ag was too large to be explained by the combined inherent
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imprecision of the assays, i.e. the source of random variation beyond criteria was not
directly related to assay imprecision.
To assess the diagnostic performance of PT, FVII:C and FVII:Ag for detection of hereditary
FVII deficiency, samples from 16 dogs were run in parallel in all three assays. For an assay
to be applicable in a situation where breeding is directed by its results, the assay must be
both very sensitive and very specific. ROC curve analysis demonstrated high discriminative
performance of both FVII:C and FVII:Ag, which were significantly superior to standard PT
measurements in detecting heterozygous carriers of G96E compared to wt/wt homozygotes.
Overlap between measurements from wt/wt homozygotes and wt/G96E heterozygotes was
seen with FVII:C, but not FVII:Ag; however, it was not possible to demonstrate a superior
performance of FVII:Ag over FVII:C, or vice versa, statistically due to the small sample
size. However, had a previously reported reference range for normal canine FVII:C, i.e. 57–
181% (Mischke, 2001), been applied in this study, all three wt/G96E heterozygotes would
have been falsely classified as normal.
A purely qualitative FVII deficiency variant with normal FVII:Ag levels, e.g. a canine
analogue to human FVII A294V (Toso et al., 2002), would potentially go undetected by the
ELISA but would be identified by specific genetic testing and in activity assays.
Accordingly, activity based assays, such as FVII:C, should not be omitted in the diagnostic
work up of canine FVII deficiency. Rather, FVII:C and FVII:Ag measurements should be
viewed as complementary in detecting FVII deficiency and genetic testing is still valuable
for confirming diagnosis in hereditary disease. Furthermore, the ELISA is not expected to
detect all cases of FVII deficiency acquired as a consequence of vitamin-K antagonism,
since FVII:Ag levels can be near normal (Takamiya and Yoshioka, 1996) and the antibodies
applied were raised against rcFVIIa lacking the Gla-domain. To enable specific detection of
vitamin-K antagonism, resulting in aberrant post-translational Gla-domain processing, a
Ca2+ dependent FVII antibody could be developed (Nakagaki et al., 1991) and applied in the
ELISA.
Taken together, FVII:Ag and also FVII:C, as configured in the present study, appears to be
valuable in the initial diagnostic work up of hereditary canine FVII deficiency, especially in
situations where time to diagnosis is essential or where the genetic test, targeting a single
mutation will fail, e.g. in promoting the discovery of new causative mutations. Activity,
antigen and gene directed assays will be valuable in complementing each other when applied
rationally in a panel to identify canine FVII deficiency.
Conclusions
A canine specific FVII ELISA was developed and validated to accurately measure FVII:Ag
in plasma. The FVII:Ag assay correctly diagnosed both homozygous and heterozygous
hereditary FVII deficiency and, together with FVII:C and gene analyses, should be valuable
in the diagnostic work up of hereditary canine FVII deficiency. FVII:Ag and FVII:C
compared favourably with PT when the diagnostic performance of these three assays to
detect heterozygous hereditary FVII deficiency was compared directly. A larger prospective
study, with establishment of absolute reference intervals, is needed to compare the
diagnostic performance of FVII:Ag and FVII:C to detect heterozygous hereditary FVII
deficiency against the current gold standard PCR method.
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Refer to Web version on PubMed Central for supplementary material.
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Standard curve for the canine specific FVII:Ag method. Optical density readings at 450 nm
obtained from duplicate measurements of samples with 0.3–30 nmol/L recombinant canine
FVII were fitted to a second order curve and used to calculate FVII:Ag in samples. A typical
curve is shown (r2 = 0.998).
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Dilution linearity for the canine specific FVII:Ag method. Dilution linearity met criteria (r2
> 0.99, slope and intercept not statistically different from 1 and 0, respectively) as assessed
by linear regression of data obtained in three runs with duplicate measurements of serially
diluted normal plasma; r2 = 0.995, slope (CI95) = [0.956; 1.024], intercept (CI95) = [−0.275;
0.518].
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Comparison of FVII:C and FVII:Ag methods to measure FVII in plasma. (A) Statistically
significant correlation between FVII:C and FVII:Ag measurements was observed with
clinical samples from dogs with clinical babesiosis (r = 0.843, CI95: [0.758; 0.899]; P <
0.0001; n = 71). When compared to total agreement (solid line), Passing–Bablock linear
regression (dotted line) did not identify disagreement between assays (P = 0.5) and no
deviation from linearity was identified (P > 0.10). (B) Bland–Altman plot with differences
between FVII:C and FVII:Ag vs. FVII:C (n = 71). Forty-three differences (61%) in total
were outside (19 above, 27%; 24 below, 34%) bounds (lines) for combined inherent
imprecision of the assays.
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Diagnostic performance of three different plasma based assays to detect hereditary FVII
deficiency. Upper panel: Plasma FVII measured by (A) prothrombin time (PT), (B) FVII
activity (FVII:C) and (C) FVII antigen (FVII:Ag) in plasma from dogs with three different
FVII genotypes.*P < 0.05,**P < 0.005. Lower panel: Receiver operator characteristic (ROC)
curve for distinction between normal dogs and FVII deficient heterozygotes, i.e. disease
gene carriers. To demonstrate diagnostic capability of an assay, the area under the ROC
curve (AUCROC) must be >0.5. Lower 95% confidence interval limits were (D) 0.453 for
PT, (E) 0.857 for FVII:C and (F) 1.0 for FVII:Ag. In comparison, AUCROC was 1.0 for
distinction between normal dogs and FVII deficient homozygotes, as well as for distinction
between by FVII deficient hetero- and homozygotes for all three assays. Data represent
means of duplicate measurements.
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Table 1
Analytical imprecision within and between assays.
Specimen Intra-assay n = 10 (singlets) Inter-assay n = 5 (duplicates)
FVII:Ag (nmol/L) CV%a FVII:Ag (nmol/L) CV%a
Low 2.0 6.1 2.0 10.0
Medium 11.4 3.2 12.3 7.9
High 23.8 2.6 23.0 5.1
FVII:Ag represents mean values.
a
CV, coefficient of variation.
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Table 2
Recovery of low, medium and high canine FVII:Ag in different matrixes (%).
Low Medium High
Canine FVII deficient plasma 97 106 106
Human normal and FVII deficient plasma 91 105 105
Buffer 96 102 100
Theoretical FVII:Ag after spiking with 3 (low), 15 (medium) and 27 (high) nM recombinant canine FVII defined as 100%. Data are baseline
corrected and reported as mean of individual runs (n = 3) with duplicate measurements in each run.
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Table 4
Mean and range of prothrombin time, FVII activity and antigen in dogs with homozygous (G96E/G96E),
heterozygous (wt/G96E) and without (wt/wt) FVII deficiency.
G96E/G96E (n = 4) wt/G96E (n = 3) wt/wt (n = 9)
PT (s) 70 (46–94) 8.0 (7.5–8.5) 7.5 (7.0–8.6)
FVII:C (%) 1.1 (0.9–1.3) 76 (65–88) 114 (80–141)
FVII:Ag (%) 2.6 (1.6–3.4) 65 (55–71) 125 (101–149)
Dogs were grouped according to FVII genotype. Data are mean (range) of duplicate measurements. Prothrombin time is reported as clotting time in
seconds. FVII activity (FVII:C) and antigen (FVII:Ag) are given relative to pooled normal canine plasma defining 100%.
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